Different chemical class, different assumptions
A lyophilised peptide is threatened mainly by proteolysis, by oxidation of a vulnerable side chain, and by freeze-thaw cycling. None of those is the dominant concern here. NAD+ is markedly hygroscopic and its pyrophosphate linkage is hydrolytically labile, which makes water the primary adversary and moisture control the discipline that determines whether a certificate still describes what you hold.
That reframing has consequences for where the material is opened. A cold vial brought into a humid Gulf laboratory and unsealed immediately draws atmospheric water directly into the powder, and the damage is not visible. Full equilibration to room temperature before breaking the seal is not a nicety for this compound; it is the control.
It is also pH sensitive in solution and degrades faster under alkaline conditions, so a stock left buffered in whatever was convenient is not a safe assumption. Prepare fresh where the assay allows, and do not treat a stored solution as carrying the certified specification forward. Defined terminology is collected in the NAD pathway glossary entry.
Plan the sub-aliquoting before the seal is broken
The catalogue presentation is a 1000 mg vial, a much larger fill than the peptide lines. In practice that makes it a bulk source for preparing reagents rather than a single-experiment unit, and the workflow question is therefore how the contents will be divided, not how the vial will be used.
Decide that before the first opening. Weighing out single-use portions under dry conditions on day one is a very different operation from returning to a partially used hygroscopic vial three times over a month, and only the first of those can be documented convincingly. Format and fill detail is set out in the NAD+ vial specifications article.
Record which portions came from which lot. A large fill divided across several storage locations generates exactly the traceability gap that a lot-linked certificate is supposed to close, unless the division itself is written down.
Receiving checks and documentation
Reconcile the invoice SKU, the printed name and fill, the lot on the vial and the lot on the certificate before anything is opened. Published records resolve through batch verification and the NAD+ certificate index; where a lot has not yet been uploaded, raise it through documentation request and record the pending status rather than releasing on the expectation that it will appear.
Laboratories that want an in-house confirmation have an easier route here than with most of the catalogue. NAD+ has a well-characterised ultraviolet absorbance profile, and an absorbance check on receipt is a routine and inexpensive integrity indicator alongside the supplied chromatographic certificate.
File the result next to the certificate rather than in an instrument folder. The pair is what an auditor asks for, and reconstructing it later from two systems is the kind of task that reliably gets deferred.
The consumer market is not your reference point
NAD+ has a large consumer presence, and the claims made in that market run well ahead of the preclinical literature. VaultLabs supplies this material as a laboratory reagent and reference standard. It is not a supplement, not a preparation for administration, and not intended for human or veterinary use.
Keep that distinction visible in internal documentation, because it is the one most likely to be blurred by someone who has encountered the compound outside a laboratory context. Ordering context, AED pricing and emirate dispatch sit on the NAD+ research UAE page; compound-specific handling notes are on the NAD storage guide, and related comparisons are at glutathione versus NAD.